J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson et al., The Pharmacology and Management of the Vitamin K Antagonists, Chest, vol.126, issue.3, pp.204-233, 2004.
DOI : 10.1378/chest.126.3_suppl.204S

B. Haury and C. Cases, Les événements indésirables graves liés aux soins observés dans les établissements de santé%: premiers résultats d'une étude nationale, DREES -Études et Résultats. mai, issue.398, 2005.

A. Castot, F. Haramburu, K. Holbrook, A. Pereira, J. Labiris et al., Hospitalisations dues aux effets indésirables des médicaments%: résultats d'une étude nationale. Point sur la nouvelle campagne d'information sur les traitements anticoagulants antivitamine K [Internet]. [cité 29 mai 2016]. Disponible sur: http://social-sante.gouv.fr Systematic overview of warfarin and its drug and food interactions, Arch Intern Med. mai, vol.165, issue.10, pp.1095-106, 2005.

S. Schulman, Advantages and limitations of the new anticoagulants, Journal of Internal Medicine, vol.369, issue.1, pp.1-11, 2014.
DOI : 10.1111/joim.12138

W. Klauser and M. Dütsch, Practical management of new oral anticoagulants after total hip or total knee arthroplasty, MUSCULOSKELETAL SURGERY, vol.31, issue.Suppl 2, pp.189-97, 2013.
DOI : 10.1007/s12306-013-0306-8

B. Eriksson, O. Dahl, M. Huo, A. Kurth, S. Hantel et al., Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*), Thrombosis and Haemostasis, vol.105, issue.4
DOI : 10.1160/TH10-10-0679

J. Ginsberg, B. Davidson, P. Comp, C. Francis, R. Friedman et al., Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery, Thromb Haemost. janv J Arthroplasty. janv, vol.10524, issue.41, pp.1-9, 2009.

J. Engl, S. Schulman, A. Kakkar, S. Goldhaber, S. Schellong et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation. févr, vol.361129, issue.17, 2009.

B. Brenner, O. Dahl, B. Eriksson, P. Mouret, and J. Muntz, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, vol.358, issue.26, 2008.

W. Ageno, L. Borris, J. Lieberman, N. Rosencher, and T. Bandel, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, Lancet Lond Engl. juill N Engl J Med, vol.372358, issue.963226, pp.2776-86, 2008.

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial, 1673?80. 22, 2009.

S. Berkowitz, B. Brenner, H. Büller, H. Decousus, and A. Gallus, Oral rivaroxaban for symptomatic venous thromboembolism, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation883?91. 23. Bauersachs R, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00724645

G. Raskob, A. Gallus, G. Pineo, D. Chen, and R. Portman, Rivaroxaban in patients with a recent acute coronary syndrome Apixaban or enoxaparin for thromboprophylaxis after knee replacement, ):9?19. 26. Lassen MR, 2009.

A. Gallus, G. Raskob, G. Pineo, D. Chen, and L. Ramirez, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, Lancet Lond Engl. 6 mars N Engl J Med, vol.375363, issue.971726, pp.2487-98, 2010.

C. Granger, J. Alexander, J. Mcmurray, R. Lopes, E. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-92, 2011.
DOI : 10.1056/NEJMoa1107039

G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus et al., Oral Apixaban for the Treatment of Acute Venous Thromboembolism, N Engl J Med, p.29
URL : https://hal.archives-ouvertes.fr/hal-00932477

R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, N Engl J Med. 28 nov N Engl J Med, vol.369369, issue.3415, pp.1406-1421, 2013.

B. Eriksson, D. Quinlan, and J. Weitz, Comparative Pharmacodynamics and Pharmacokinetics of Oral??Direct Thrombin and??Factor??Xa Inhibitors in Development, Clinical Pharmacokinetics, vol.5, issue.16, pp.1-22, 2009.
DOI : 10.2165/0003088-200948010-00001

J. Stangier and A. Clemens, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Clinical and Applied Thrombosis/Hemostasis, vol.24, issue.1
DOI : 10.1177/1076029609343004

A. Thromb, D. Pinto, and D. Zhang, Pharmacokinetics and Pharmacodynamics of Rivaroxaban ? An Oral, Direct Factor Xa Inhibitor Rivaroxaban%: summary of product characteristics [Internet]. www.ema.europa.eu. [cité 12 juill 2015] Disponible sur: http://www.ema.europa Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor Apixaban%: summary of product characteristics [Internet, 9S ? 16S. 37. Kreutz R75?83. 38. European Medicines Agency478?92. 40. European Medicines Agency and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. ! 97, 2009.

M. Becka, M. Zuehlsdorf, W. Mueck, and R. Garcia, Healthy Volunteers and Patients Undergoing Total Hip Replacement Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59?7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects, 555?65. 43. Kubitza D, pp.549-58, 2005.

. Apixaban, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects, Br J Clin Pharmacol. févr, vol.75, issue.2, pp.476-87, 2013.

J. Mendell, M. Tachibana, M. Shi, S. Kunitada, J. Stangier et al., an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers European Medicines Agency Edoxaban%: summary of product characteristics Disponible sur: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002629/WC500189045.pdf 47 Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939?an oral, direct Factor Xa inhibitor?after multiple dosing in healthy male subjects, Effects of Food on the Pharmacokinetics of Edoxaban873?80. 49. European Medicines Agency. Dabigatran%: summary of product characteristics [Internet, pp.687-94, 2005.

S. Blech, T. Ebner, E. Ludwig-schwellinger, J. Stangier, and W. Roth, The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans, Drug Metabolism and Disposition, vol.36, issue.2, pp.386-99, 2008.
DOI : 10.1124/dmd.107.019083

C. Weinz, U. Buetehorn, H. Daehler, C. Kohlsdorfer, U. Pleiss et al., Pharmacokinetics of BAY 59-7939 ??? an oral, direct Factor Xa inhibitor ??? in rats and dogs, 891?910. 53. Bounameaux H, Camm AJ. Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor, pp.1209-1240, 2005.
DOI : 10.1080/00498250500250493

J. Weitz, C. Frost, Z. Yu, K. He, H. Zhang et al., New Anticoagulants for Treatment of Venous Thromboembolism Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans, ):59?68. 55. Gross PL380?6. 56. Raghavan N, pp.74-81, 2008.

J. Stangier, Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate, 285?95. 58, 2008.
DOI : 10.2165/00003088-200847050-00001

. Pharmacokinetics, M. Biotransformation, . Balance-of-edoxaban, and . Selective, Direct Factor Xa Inhibitor, in Humans, Drug Metab Dispos. 1 déc, vol.40, issue.12, pp.2250-2255, 2012.

J. Stangier, K. Rathgen, H. Stähle, D. Gansser, W. Roth et al., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor, 249?55. 61. Frost CE, 2007.

A. Kubitza, D. Becka, M. Zuehlsdorf, M. Mueck, and W. , Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects, 651?62. ! 99! 62, pp.218-244, 2007.
DOI : 10.1177/0091270006296058

V. Upreti, J. Wang, Y. Barrett, W. Byon, R. Boyd et al., Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects, ):908?16. 64. Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology, 2013.
DOI : 10.1111/bcp.12114

J. Graff, S. Harder, A. Halabi, D. Kubitza, M. Zuehlsdorf et al., Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban -an oral, direct factor Xa inhibitor. Abstract P-M-635, Clin Pharmacokinet. avr J Thromb Haemost. juill, vol.525, issue.66, 2007.

J. Stangier, K. Rathgen, H. Stähle, D. Mazur, M. Becka et al., Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate, Clinical Pharmacokinetics, vol.19, issue.3, pp.703-715, 2010.
DOI : 10.2165/11318170-000000000-00000

M. Chang, Z. Yu, A. Shenker, J. Wang, J. Pursley et al., Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban, The Journal of Clinical Pharmacology, vol.21, issue.5
DOI : 10.1002/jcph.633

. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with endstage renal disease on hemodialysis, J Clin Pharmacol. mai, vol.56, issue.5, pp.628-664, 2016.

C. Lee and J. Ansell, Direct thrombin inhibitors, British Journal of Clinical Pharmacology, vol.103, issue.1, pp.581-92, 2011.
DOI : 10.1111/j.1365-2125.2011.03916.x

T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller et al., Measuring oral direct inhibitors of thrombin and factor??Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol.123, issue.4, pp.756-60, 2013.
DOI : 10.1111/jth.12149

V. Siguret, I. Gouin-thibault, and P. Sié, Dabigatran etexilate et examens de biologie médicale [Internet]. GEHT; mars 2013 [cité 5 avr 2016] Disponible sur: http://site.geht.org/UserFiles/file/NACO/Dabigatran_tests_biologiques_GEHT.pdf 74. Praxbind (Idarucizumab)%: summary of product characteristics, WC500197462.pdf 75. Pollack CV, pp.511-531, 2015.

J. Ansell, S. Bakhru, B. Laulicht, S. Steiner, M. Grosso et al., Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban, New England Journal of Medicine, vol.371, issue.22, pp.2141-2143, 2014.
DOI : 10.1056/NEJMc1411800

B. Laulicht, S. Bakhru, C. Lee, C. Baker, X. Jiang et al., Abstract 11395: Small Molecule Antidote for Anticoagulants. Circulation, 2012.

P. Reilly, T. Lehr, S. Haertter, S. Connolly, S. Yusuf et al., Disponible sur: http://www.jle.com/fr/revues/abc/e-docs/anticoagulants_directs_oraux_actualites_ pour_les_biologistes_304370/article.phtml 80 The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, Anticoagulants directs oraux: actualités pour les biologistes, pp.2015-333, 2014.

J. Stangier, H. Stähle, K. Rathgen, K. Reseski, and T. Körnicke, Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact ! 101! on the pharmacokinetics of either drug. Abstract P-T-677, J Thromb Haemost, vol.5, 2007.

J. Stangier, H. Stähle, K. Rathgen, W. Roth, K. Shakeri-nejad et al., Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin, J Clin Pharmacol. déc J Clin Pharmacol. sept, vol.4846, issue.129, pp.981-90, 2006.

J. Laroche, Nouveaux anticoagulants 2013 MTEV Aspects pratiques [Internet]. [cité 16, Disponible sur, 2016.

J. Douxfils, C. Chatelain, B. Chatelain, J. Dogné, and F. Mullier, Disponible sur: http://site.geht.org/UserFiles/file/ NACO/Rivaroxaban_tests_biologiques_GEHT.pdf 86 Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide: Thromb Haemost. 13 juin 2013, GEHT; 2012 oct, pp.283-94

S. Asirvatham, T. Hu, V. Vaidya, T. Thiele, and K. Selleng, Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag Reversal of anticoagulants: an overview of current developments: Thromb Haemost. 2 avr 2015, ):931?42. 90, 2016.

M. Zafar, D. Vorchheimer, J. Gaztanaga, M. Velez, D. Yadegar et al., daiichi-sankyo- anticoagulant-edoxaban-succeeds-in-phase-iii/ 92 Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review, Disponible sur883?8. 93. Cuker A, Husseinzadeh H, pp.288-94, 2007.

. Randomized, . Double-blind, J. Mendell-harary, M. Tachibana, H. Masumoto et al., Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects, 4269?4269. 95. Ogata K743?53. 96. Zahir H, pp.166-75, 2010.

J. Mendell, R. Noveck, and M. Shi, A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin, British Journal of Clinical Pharmacology, vol.160, issue.Suppl 2, pp.966-78, 2013.
DOI : 10.1111/j.1365-2125.2012.04409.x

Y. Koretsune, T. Yamashita, and M. Yasaka, Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment, European Heart Journal, vol.34, issue.suppl 1, p.520, 2013.
DOI : 10.1093/eurheartj/eht307.P520

L. He, Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis, Thromb Haemost. avr, vol.113, issue.4, pp.719-746, 2015.

K. Baxter, Stockley's Drug Interactions: A source book of interactions, their mechanisms, clinical importance and management. 10 th edition, 2013.

G. Lippi, E. Favaloro, and C. Mattiuzzi, Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring? Semin Thromb Hemost, 11 juin, vol.40, issue.07, pp.756-65, 2014.

F. Lemaitre, Les interactions médicamenteuses [Internet] Disponible sur: https, 2014.

J. Yu, T. Ritchie, A. Mulgaonkar, and I. Ragueneau-majlessi, Drug Disposition and Drug-Drug Interaction Data in 2013 FDA New Drug Applications: A Systematic Review, Drug Metabolism and Disposition, vol.42, issue.12, 2014.
DOI : 10.1124/dmd.114.060392

P. Chin, J. Vella-brincat, S. Walker, M. Barclay, and E. Begg, Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital, Internal Medicine Journal, vol.7, issue.Suppl 2, pp.778-83, 2013.
DOI : 10.1111/imj.12170

C. Mcdonald, K. Ellett, L. Barratt, J. Caughey, and G. , An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran, Pharmacoepidemiology and Drug Safety, vol.23, issue.10, pp.399-405, 2015.
DOI : 10.1002/pds.3648

W. Pfeilschifter, S. Luger, R. Brunkhorst, E. Lindhoff-last, and C. Foerch, The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation, Cerebrovascular Diseases, vol.36, issue.2
DOI : 10.1159/000352062

D. Kubitza, M. Becka, B. Voith, and M. Zuehlsdorf, Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 -an Oral, Direct Factor Xa Inhibitor. Abstract P1704, J Thromb Haemost. août, vol.3, 2005.

Y. Barrett, J. Wang, Y. Song, J. Pursley, P. Wastall et al., A ! 104! randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects: Thromb Haemost, pp.916-940, 2012.

D. Kubitza, M. Becka, W. Mück, and J. Krätzschmar, Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects, British Journal of Clinical Pharmacology, vol.130, issue.2, pp.353-63, 2014.
DOI : 10.1111/bcp.12349

. Apixaban-vs, warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial, Eur Heart J. 2 janv, vol.35, issue.4, pp.224-256, 2014.

J. Mendell, F. Lee, S. Chen, V. Worland, M. Shi et al., The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor, Journal of Cardiovascular Pharmacology, vol.62, issue.2, pp.212-233, 2013.
DOI : 10.1097/FJC.0b013e3182970991

D. Kubitza, M. Becka, W. Mück, and S. Schwers, Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study, Pharmaceuticals, vol.5, issue.12, pp.279-96, 2012.
DOI : 10.3390/ph5030279

D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf, Rivaroxaban (BAY 59-7939) ? an oral, direct Factor Xa inhibitor ? has no clinically relevant interaction with naproxen, British Journal of Clinical Pharmacology, vol.35, issue.2, pp.469-76, 2007.
DOI : 10.1378/chest.126.3_suppl.338S

B. Eriksson, N. Rosencher, R. Friedman, M. Homering, and O. Dahl, Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty, Thrombosis Research, vol.130, issue.2, pp.147-51, 2012.
DOI : 10.1016/j.thromres.2011.12.005

K. Azad, Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study), Am J Cardiol. nov, vol.100, issue.9, pp.1419-1445, 2007.

L. Jungbauer, C. Dobias, C. Stöllberger, and F. Weidinger, The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation, Journal of Thrombosis and Haemostasis, vol.25, issue.9
DOI : 10.1111/j.1538-7836.2010.03943.x

K. Liesenfeld, T. Lehr, C. Dansirikul, P. Reilly, S. Connolly et al., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial, Journal of Thrombosis and Haemostasis, vol.16, issue.11, pp.2168-75, 2011.
DOI : 10.1111/j.1538-7836.2011.04498.x

M. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, and S. Sandmann, In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban, Journal of Pharmacology and Experimental Therapeutics, vol.338, issue.1, pp.372-80, 2011.
DOI : 10.1124/jpet.111.180240

J. Mendell, H. Zahir, N. Matsushima, R. Noveck, F. Lee et al., Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor, American Journal of Cardiovascular Drugs, vol.31, issue.7???8, pp.331-373, 2013.
DOI : 10.1007/s40256-013-0029-0

T. Inhibitor, With Coadministration of Digoxin, J Clin Pharmacol. févr, vol.52, issue.2, pp.243-50, 2012.

D. Kubitza, M. Becka, A. Roth, and W. Mueck, Absence of Clinically Relevant Interactions Between Rivaroxaban ??? An Oral, Direct Factor Xa Inhibitor ??? And Digoxin or Atorvastatin in Healthy Subjects, Journal of International Medical Research, vol.40, issue.5, pp.1688-707, 2012.
DOI : 10.1177/030006051204000508

J. Mendell, R. Noveck, and M. Shi, Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination, Journal of Cardiovascular Pharmacology, vol.60, issue.4, pp.335-376, 2012.
DOI : 10.1097/FJC.0b013e31826265b6.

J. Mendell, R. Noveck, H. Zahir, F. Lee, V. Petrushun et al., The effect of quinidine and verapamil, p glycoprotein/cyp3a4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Abstract No 2848, Basic Clin Pharmacol Toxicol. 1 juill, vol.107, p.450, 2010.

C. Frost, W. Byon, Y. Song, J. Wang, A. Schuster et al., Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.55, issue.Suppl. 1, pp.838-884, 2015.
DOI : 10.1111/bcp.12541

S. Härtter, R. Sennewald, G. Nehmiz, and P. Reilly, ) after co-medication with verapamil in healthy subjects, British Journal of Clinical Pharmacology, vol.363, issue.Suppl. 1, pp.1053-62, 2013.
DOI : 10.1111/j.1365-2125.2012.04453.x

. Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation, J

X. Delavenne, E. Ollier, T. Basset, L. Bertoletti, S. Accassat et al., A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin, British Journal of Clinical Pharmacology, vol.33, issue.1, pp.107-120, 2013.
DOI : 10.1111/bcp.12055

W. Mueck, D. Kubitza, and M. Becka, Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects, British Journal of Clinical Pharmacology, vol.61, issue.Suppl.
DOI : 10.1111/bcp.12075

S. Härtter, M. Koenen-bergmann, A. Sharma, G. Nehmiz, U. Lemke et al., Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin, British Journal of Clinical Pharmacology, vol.86, issue.2, pp.490-500, 2012.
DOI : 10.1111/j.1365-2125.2012.04218.x

. Rivaroxaban, &. Johnson, &. Research, . Development, C. Frost et al., Disponible sur : http://www.fda.gov, 2011.

J. Mendell, S. Chen, L. He, M. Desai, and D. Parasramupria, The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults, Clinical Drug Investigation, vol.319, issue.2, pp.447-53, 2015.
DOI : 10.1007/s40261-015-0298-2

J. Mendell, K. Lasseter, and M. Shi, Effect of esomeprazole on edoxaban pharmacokinetics and pharmacodynamics when administered orally as tablets and as solution. Abstract P1052, Europace, vol.13, issue.3, 2011.

V. Upreti, . Song, . Wang, . Byon, . Boyd et al., Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor, Clinical Pharmacology: Advances and Applications, vol.59, 2013.
DOI : 10.2147/CPAA.S41999

A. Wannhoff, K. Weiss, P. Schemmer, W. Stremmel, and D. Gotthardt, Increased Levels of Rivaroxaban in Patients After Liver Transplantation Treated With Cyclosporine A, Transplantation, vol.98, issue.2
DOI : 10.1097/TP.0000000000000223

C. Stöllberger and J. Finsterer, Relevanz von P-Glykoprotein in der Schlaganfallpr??vention mit Dabigatran, Rivaroxaban und Apixaban, S2):140?5. ! 108, 2015.
DOI : 10.1007/s00059-014-4188-9

R. Tadros and S. Shakib, Warfarin: Indications, risks and drug interactions, Aust Fam Physician, vol.39, issue.7, p.476, 2010.

H. Périopératoire, Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants, Crit Care. 29 Avr, vol.19, p.203, 2015.